Kikuchi Yoshinori, Yamaguchi Kazuhisa, Shimizu Ryo, Matsumoto Yuu, Kurose Yasuko, Okano Naoki, Otsuka Yuichirou, Shibuya Kazutoshi, Matsuda Takahisa, Shimada Hideaki
Department of Clinical Oncology, Toho University, 6-11-1 Omori-nishi, Ota-ku, Tokyo, 143-8541 Japan.
Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), Toho University, Tokyo, Japan.
Int Cancer Conf J. 2023 Jul 3;12(4):285-290. doi: 10.1007/s13691-023-00619-5. eCollection 2023 Oct.
Intrahepatic cholangiocarcinoma is a condition with a poor prognosis. Traditionally, there was no cure unless important drugs such as gemcitabine, cisplatin, and tegafur/gimeracil/uracil potassium showed efficacy. Pemigatinib has recently become accessible for the treatment of intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement gene abnormalities. Hyperphosphatemia is typically linked to pemigatinib. In the current case, pemigatinib was used to effectively treat a 48-year-old woman, and hypophosphatemia was observed. Patients with intrahepatic cholangiocarcinoma should undergo aggressive cancer multigene panel testing as well as careful monitoring of serum phosphorus levels.
肝内胆管癌是一种预后较差的疾病。传统上，除非吉西他滨、顺铂和替吉奥等重要药物显示出疗效，否则无法治愈。培米替尼最近已可用于治疗具有FGFR2融合或重排基因异常的肝内胆管癌。高磷血症通常与培米替尼有关。在本病例中，培米替尼被用于有效治疗一名48岁女性，并观察到了低磷血症。肝内胆管癌患者应进行积极的癌症多基因检测，并仔细监测血清磷水平。
